Roche gets EC nod for Tecentriq plus Abraxane to treat metastatic TNBC

This article was originally published here

The approval has been granted for Tecentriq plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) to treat adult patients with unresectable locally advanced or metastatic

The post Roche gets EC nod for Tecentriq plus Abraxane to treat metastatic TNBC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply